Diabetes drugs show anti-ageing promise, but human proof remains elusive

A review of eight diabetes drug classes finds promising laboratory and cardiovascular evidence, but says none can yet be confirmed as an ageing-slowing treatment.

A new review from researchers in Kunming has revived an old question in a broader form: if type 2 diabetes appears to speed up biological ageing, could the drugs used to treat it also slow that process down? The paper, published in Pharmacological Research, examines eight classes of glucose-lowering medicines and weighs the evidence for whether any of them deserve to be called geroprotective, or ageing-slowing, treatments. The review argues that diabetes resembles ageing in fast-forward, with links to telomere shortening, chronic inflammation, mitochondrial decline and cellular senescence, while metformin remains the best-known candidate in the field.

Metformin still has the broadest mechanistic case. A review in the National Library of Medicine’s PubMed Central says the drug has been tied to many of the recognised hallmarks of ageing, including damaged mitochondria, inflammation, impaired autophagy, telomere attrition and senescent cells. The Kunming authors also note that metformin’s reach extends beyond blood sugar, affecting pathways such as AMPK and mTOR, which are involved in cellular energy sensing and growth control. But the clinical picture is less persuasive: a trial in older adults with frailty or sarcopenia found no improvement in walking speed, grip strength or frailty, and another study suggested the drug could blunt some of the mitochondrial gains usually seen after aerobic exercise.

The review places newer diabetes drugs closer to the front of the pack on real-world health outcomes. According to systematic reviews of older adults with type 2 diabetes, GLP-1 receptor agonists lowered major cardiovascular events, cardiovascular death, stroke and heart attack, while SGLT-2 inhibitors cut major cardiovascular events and heart-failure hospitalisations. Those findings do not prove that either class slows ageing itself, but they do suggest benefits that reach well beyond glucose control. The Kunming authors also say GLP-1 medicines such as semaglutide may have anti-inflammatory effects and possible brain protection, while SGLT-2 inhibitors such as empagliflozin and dapagliflozin appear to mimic some features of fasting.

Acarbose, an older drug that slows the breakdown of starches after meals, stands out in the animal literature. The review says it has the most reproducible evidence for extending lifespan in mice, although translating that result to people remains speculative. That caution runs through the entire paper. The authors say that despite strong laboratory signals, the human evidence is still limited by differences between models, too few randomised trials and not enough long-term follow-up. They argue that questions of timing, dose, tissue targeting and patient selection will determine whether these medicines can ever be repurposed safely as ageing therapies.

The practical message is more restrained than the headline debate might suggest. The review’s evidence points most clearly to good glucose control, because the harms associated with diabetes appear to track with biological ageing in several organs, including the brain and muscle. But it also warns against assuming that an ageing signal in the lab automatically translates into longer, healthier lives in humans. For now, the strongest case for these drugs remains in diabetes care itself, where some classes already have clear cardiovascular and kidney benefits, rather than in the still-unproven promise of anti-ageing treatment.